The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19)
has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical …

Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) vaccineare a promising
platform to prevent infectious diseases as demonstrated by the recent success of SARS-CoV …

Messenger RNA (mRNA) has received great attention in the prevention and treatment of
various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA …

Ionizable lipid nanoparticles (LNPs) are the most clinically advanced nonviral platform for
mRNA delivery. While they have been explored for applications including vaccines and …

Lipid nanoparticles (LNPs) are a potent delivery technology that have made it possible for
the recent clinical breakthroughs in mRNA therapeutics and vaccines. A key challenge to the …

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of
gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented …

Fully targeted mRNA therapeutics necessitate simultaneous organ-specific accumulation
and effective translation. Despite some progress, delivery systems are still unable to fully …

Several studies have utilized a lipid nanoparticle delivery system to enhance the
effectiveness of mRNA therapeutics and vaccines. However, these nanoparticles are …

During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed
nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein …